Skip to main content

Viral Shedding and Infectivity Testing in Clinical Trials of Oncolytic Virotherapy

Join Eurofins Viracor BioPharma for our next webinar, "Viral shedding and infectivity testing in clinical trials of oncolytic virotherapies", presented by Kristen Mickey, MS, Research Scientist, R&D.

Developments in molecular and genomics technologies are dramatically improving the opportunities for development of more effective cancer therapeutics. We offer a broad range of molecular and genomic services to support translational and precision medicine approaches to clinical development. With a wide range of viral and bacterial targets, our clients have access to a broad menu of real-time PCR and quantitative assays for pathogen detection and monitoring, biodistribution and shedding.
Our PCR technology expertise includes: qPCR, RT-PCR, TEM-PCR, ddPCR; and extends across a variety of applications and therapeutic areas.

  • What will you learn?
    • Importance of the use of shedding and infectivity assays in a successful oncolytic viral drug trial
    • Why implementing qPCR assays are crucial to providing rapid and accurate data on viral shedding and biodistribution  
    • How implementing TCID50 assays to measure infectivity provides vital information for virus viability shed from an injection site
    • Regulatory and technical considerations for designing and validating qPCR and TCID50 assays in a clinical testing setting
    • Development and validation overview and design for shedding and infectivity studies

REGISTRATION 

 

 

 

Back to top